Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

INTRODUCTION: This study assessed baseline cardiovascular (CV) risk factors, concomitant CV medication use, risk of major adverse cardiac events-plus (MACE-plus), and bleeding adverse events (AEs) in patients with idiopathic pulmonary fibrosis (IPF) in three randomized, placebo-controlled phase III...

Descripción completa

Detalles Bibliográficos
Autores principales: Glassberg, Marilyn K., Nathan, Steven D., Lin, Chin-Yu, Morgenthien, Elizabeth A., Stauffer, John L., Chou, Willis, Noble, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822835/
https://www.ncbi.nlm.nih.gov/pubmed/31401786
http://dx.doi.org/10.1007/s12325-019-01052-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822835/
https://www.ncbi.nlm.nih.gov/pubmed/31401786
http://dx.doi.org/10.1007/s12325-019-01052-y

Ejemplares similares